Pharma Industry News | PharmaNewsDaily.com

Home » Archives by category » Pharma Industry News

Frazier Healthcare Partners raises $617m for life sciences fund

Frazier Healthcare Partners has closed its third life sciences fund – Frazier Life Sciences X, at more than $617 million in capital commitments. The Seattle-based private equity and venture capital firm has been investing in life sciences since more than 29 years ago Since its inception, Frazier Healthcare Partners has raised its total committed capital to approximately $4.8 […]

January 19, 2020No CommentRead More

Merck acquires ArQule for $2.7bn to further diversify oncology pipeline

January 18, 2020 No Comment

Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the latest pharma acquisition news. The pharma giant announced the deal in December 2019 in a move to further diversify its oncology pipeline with the Massachusetts-based ArQule focused on developing kinase […]

Lilly to acquire US dermatology drug company Dermira for $1.1bn

January 13, 2020 No Comment

Lilly acquisition of Dermira : US pharma giant Eli Lilly and Company (Lilly) has agreed to acquire California-based dermatology drug company Dermira for about $1.1 billion in an all-cash deal as per the latest pharma acquisition news. Dermira, which is being acquired for $18.75 per share, has been engaged in developing dermatology products for the […]

NeuroBo, Gemphire merger wrapped up to form neurodegenerative disease company

January 13, 2020 No Comment

NeuroBo Pharmaceuticals, a Boston-based clinical-stage pharma company, has wrapped up its previously announced merger with Gemphire Therapeutics, a Michigan-based clinical-stage biopharma company focused on developing therapies for dyslipidemia and nonalcoholic fatty liver disease (NASH). The new combined company will be called NeuroBo Pharmaceuticals, which will focus on advancing a clinical-stage pipeline targeting neurodegenerative diseases. NeuroBo, […]

Taro recalls lot of Lamotrigine tablets in US due to contamination

January 12, 2020 No Comment

Taro Pharmaceuticals U.S.A. has issued to recall of a lot of Lamotrigine 100 mg tablets owing to cross-contamination with a trace of another drug substance – Enalapril Maleate. Lamotrigine is indicated for the treatment of epilepsy and bipolar disorders. The US pharmaceutical manufacturer is recalling Lot # 331771, which has an expiration date June 2021 […]

PACT Pharma raises $75m to develop neoTCR-T cell therapies for solid tumors

January 11, 2020 No Comment

PACT Pharma, a California-based clinical stage company, which is focused on developing fully personalized neoTCR-T cell therapies for solid tumors, has raised $75 million in a Series C financing round. The funding round was led by Vida Ventures, a life science venture firm, with participation from the current investors of PACT Pharma. The clinical stage […]

ATAI Life Sciences partners with Neuronasal to develop concussion treatment

January 7, 2020 No Comment

ATAI Life Sciences, a German biotech company focused on developing drugs for mental illnesses, has partnered with Neuronasal to develop a short-term treatment for mild traumatic brain injury (mTBI) or concussion. Neuronasal’s concussion treatment includes the intranasal delivery of low doses of N-acetylcysteine (NAC) to patients with acute concussion. N-acetylcysteine has been safely used for […]

Chinese pharma company CF PharmTech raises $90m for respiratory drugs

January 6, 2020 No Comment

Chinese pharma company CF PharmTech has secured a $90 million Series E investment led by New Alliance Capital for accelerating the global development of respiratory drugs. The investment round saw participation from new investors such as CR-CP Life Science Fund, Finnova Capital, Xiangcheng Financial, GT Capital, Co-stone Asset Management, and Everest Venture Capital. Existing investors […]

Astellas Pharma acquires US biotech company Xyphos Biosciences

December 28, 2019 No Comment

Astellas acquisition of Xyphos : Japanese pharma company Astellas Pharma has acquired US biotech company Xyphos Biosciences in a deal worth up to $665 million as per the latest pharma acquisition news. The acquisition of Xyphos Biosciences gives Astellas Pharma access to the former’s ACCEL technology platform alongside its immuno-oncology talent to develop new and […]

Roche signs $2.85bn deal with Sarepta for SRP-9001 DND gene therapy

December 24, 2019 No Comment

Roche has signed a licensing deal worth up to $2.85 billion with Sarepta Therapeutics for the exclusive ex-US commercial rights to the latter’s SRP-9001 (AAVrh74.MHCK7.micro-dystrophin), an investigational gene therapy for Duchenne muscular dystrophy (DMD). As per the agreement terms, Sarepta Therapeutics will get an upfront payment made up of $750 million in cash and $400 […]